Bill SponsorBILLSPONSOR
Bill Sponsor
Politicians
Bills
House Bill 8454
117th Congress(2021-2022)
Medical Marijuana and Cannabidiol Research Expansion Act
Became Law
Became Law
Became Public Law 117-215 on Dec 2, 2022
Overview
Text
Introduced
Jul 21, 2022
Latest Action
Dec 2, 2022
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
8454
Congress
117
Policy Area
Crime and Law Enforcement
Crime and Law Enforcement
Primary focus of measure is criminal offenses, investigation and prosecution, procedure and sentencing; corrections and imprisonment; juvenile crime; law enforcement administration. Measures concerning terrorism may fall under Emergency Management or International Affairs policy areas.
Sponsorship by Party
Democrat
Earl Blumenauer
Oregon
Democrat
Barbara Lee
California
Democrat
Ed Perlmutter
Colorado
Democrat
Eleanor Holmes Norton
District of Columbia
Republican
Andy Harris
Maryland
Democrat
Debbie Dingell
Michigan
Democrat
Chris Pappas
New Hampshire
Republican
Dave Joyce
Ohio
Republican
Nancy Mace
South Carolina
Democrat
Steve Cohen
Tennessee
Republican
Morgan Griffith
Virginia
House Votes (1)
Senate Votes (1)
checkPassed on July 27, 2022
Question
On Motion to Suspend the Rules and Pass, as Amended
Status
Passed
Type
Roll Call Vote
Roll Call Vote
A vote that records the individual position of each Member who voted. Such votes occurring on the House floor (by the "yeas and nays" or by "recorded vote") are taken by electronic device. The Senate has no electronic voting system; in such votes, Senators answer "yea" or "nay" as the clerk calls each name aloud. Each vote is compiled by clerks and receives a roll call number (referenced in Congress.gov as a "Record Vote" [Senate] or "Roll no." [House]).
Roll Call Type
2/3 Yea-And-Nay
Roll Number
392
House Roll Call Votes
Summary

Medical Marijuana and Cannabidiol Research Expansion Act

This bill establishes a new, separate registration process to facilitate research on marijuana.

Specifically, the bill directs the Drug Enforcement Administration (DEA) to follow procedures specified in the bill to register (1) practitioners to conduct marijuana research, and (2) manufacturers to supply marijuana for the research.

The bill allows certain registered entities (including institutions of higher education, practitioners, and manufacturers) to manufacture, distribute, dispense, or possess marijuana or cannabidiol (CBD) for the purposes of medical research. Additionally, the bill directs the DEA to register manufacturers and distributors of CBD or marijuana for the purpose of commercial production of an approved drug that contains marijuana or its derivative.

Finally, the bill includes various other provisions, including provisions that

  • require the DEA to assess whether there is an adequate and uninterrupted supply of marijuana for research purposes;
  • prohibit the Department of Health and Human Services (HHS) from reinstating the interdisciplinary review process for marijuana research;
  • allow physicians to discuss the potential harms and benefits of marijuana and its derivatives (including CBD) with patients; and
  • require HHS, in coordination with the National Institutes of Health and relevant federal agencies, to report on the therapeutic potential of marijuana for various conditions such as epilepsy, as well as the impact on adolescent brains and on the ability to operate a motor vehicle.
Text (4)
Enrolled Bill
Received in Senate
July 27, 2022
Engrossed in House
July 26, 2022
Introduced in House
July 21, 2022
Related Bills (1)
Mar 24, 2022
Passed Senate
11
Sponsorship
Senate Bill 253
Cannabidiol and Marihuana Research Expansion Act
Active
Amendments
Type
Related Bill
Related Bill
A related bill may be a companion measure, an identical bill, a procedurally-related measure, or one with text similarities. Bill relationships are identified by the House, the Senate, or CRS, and refer only to same-Congress measures.
Identified By
CRS
Actions (17)
12/02/2022
Became Public Law No: 117-215.
12/02/2022
Signed by President.
11/29/2022
Presented to President.
11/17/2022
Message on Senate action sent to the House.
11/16/2022
Passed Senate without amendment by Voice Vote. (consideration: CR S6746-6747)
11/16/2022
Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.
07/27/2022
Received in the Senate, read twice.
07/26/2022
Motion to reconsider laid on the table Agreed to without objection.
07/26/2022
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 325 - 95 (Roll no. 392). (text: CR H7120-7122)
07/26/2022
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 325 - 95 (Roll no. 392).(text: CR H7120-7122)
07/26/2022
Considered as unfinished business. (consideration: CR H7145-7146)
07/26/2022
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
07/26/2022
DEBATE - The House proceeded with forty minutes of debate on H.R. 8454.
07/26/2022
Considered under suspension of the rules. (consideration: CR H7120-7124)
07/26/2022
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
07/21/2022
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
07/21/2022
Introduced in House
Public Record
Record Updated
Sep 5, 2023 5:28:35 PM
Copyright © 2024 Civic Bits LLC
Privacy Policy
Terms of Service
What's New
About